Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 53

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 8
Chunk 53
---
, eye inflammation, ocular hypertension, dry eyes and retinal diseases.•The Surgical segment consists of sales of medical device equipment, consumables and technologies for the treatment of cataracts, corneal, vitreous and retinal eye conditions, which includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery.The Company’s Chief Operating Decision Maker uses segment profit to assess operating performance and make resource allocation decisions for each of its segments. Segment profit is based on operating income (loss) after the elimination of 

29

intercompany transactions. Certain costs, such as Amortization of intangible assets, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of Bausch + Lomb’s businesses and incurs certain expenses, gains and losses related to the overall management of Bausch + Lomb, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.Segment Revenues and ProfitSegment revenues and profits for the three and nine months ended September 30, 2025 and 2024 were as follows:Vision CarePharmaceuticalsSurgicalTotalThree Months Ended September 30,(in millions)20252024202520242025202420252024RevenuesProduct Sales$734 $682 $329 $305 $214 $205 $1,277 $1,192 Other Revenues2 2 1 1 1 1 4 4 736 684 330 306 215 206 1,281 1,196 ExpensesCost of goods sold (excluding amortization and impairments of intangible assets)279 252 106 93 124 119 Cost of other revenues— — 1 — — — Selling, general and administrative225 219 132 137 72 64 Research and development15 12 15 7 11 10 Segment Profit$217 $201 $76 $69 $8 $13 301 283 Corporate(153